Back to Journals » Research and Reports in Tropical Medicine » Volume 6

Mycetoma: epidemiology, treatment challenges, and progress

Authors Taha H, Fahal A, van de Sande W

Received 25 February 2015

Accepted for publication 13 April 2015

Published 5 June 2015 Volume 2015:6 Pages 31—36

DOI https://doi.org/10.2147/RRTM.S53115

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Thomas Unnasch


Hala Taha Mohamed,1 Ahmed Fahal,1 Wendy WJ van de Sande2

1Mycetoma Research Center, University of Khartoum, Khartoum, Sudan; 2Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands

Abstract: Mycetoma is a chronic infectious disease of the subcutaneous tissue with a high morbidity. This disease is most commonly seen in countries between 30°N and 15°S of the equator, but cases have also been seen in Europe and the USA. Due to the lack of proper prevalence data, currently the true burden of this disease is not known. Mycetoma can be caused by a large variety of microorganisms, both bacteria and fungi. Treatment of the disease depends on the etiology of the causative agent. Actinomycetoma is usually treated with antibiotics only and has a decent cure rate; eumycetoma is treated with a combination of antibiotics and surgery. Unfortunately, for eumycetoma, recurrent infections are common and amputations are still needed in a large proportion of the patients.

Keywords: eumycetoma, actinomycetoma, epidemiology, etiology, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]